Combination Analysis in Genetic Polymorphisms of Drug-metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2015 Jan 2

PMID 25552922

Citations 27

Authors

Tomoko Ota

Yuka Kamada

Mariko Hayashida

Kyoko Iwao-Koizumi

Shigenori Murata

Kenji Kinoshita

Affiliations

Soon will be listed here.

Abstract

The Cytochrome P450 is the major enzyme involved in drug metabolism. CYP enzymes are responsible for the metabolism of most clinically used drugs. Individual variability in CYP activity is one important factor that contributes to drug therapy failure. We have developed a new straightforward TaqMan PCR genotyping assay to investigate the prevalence of the most common allelic variants of polymorphic CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese population. Moreover, we focused on the combination of each genotype for clinical treatment. The genotype analysis identified a total of 139 out of 483 genotype combinations of five genes in the 1,003 Japanese subjects. According to our results, most of subjects seemed to require dose modification during clinical treatment. In the near future, modifications should be considered based on the individual patient genotype of each treatment.

Citing Articles

Impact of fresh grape juice on the pharmacokinetics of omeprazole: results of a food-drug interaction study.

Iftikhar T, Iqbal Z, Shah Y, Khan N, Abbas M, Shehzad O Front Pharmacol. 2024; 15:1467805.

PMID: 39697543 PMC: 11652163. DOI: 10.3389/fphar.2024.1467805.

Identification of Novel Quinolone and Quinazoline Alkaloids as Phosphodiesterase 10A Inhibitors for Parkinson's Disease through a Computational Approach.

Ahmad I, Khalid H, Perveen A, Shehroz M, Nishan U, Rahman F ACS Omega. 2024; 9(14):16262-16278.

PMID: 38617664 PMC: 11007772. DOI: 10.1021/acsomega.3c10351.

Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea.

Huh K, Hwang S, Na J, Yu K, Jang I, Chung J Clin Transl Sci. 2024; 17(3):e13772.

PMID: 38501281 PMC: 10949179. DOI: 10.1111/cts.13772.

CYP2C19 gene polymorphism in Ningxia.

Yang Z, Xie Y, Zhang D, Zou Y, Li X, Chen R Pharmacol Rep. 2023; 75(3):705-714.

PMID: 36913175 DOI: 10.1007/s43440-023-00473-5.

Ethnicity-based classifications and medical genetics: One Health approaches from a Western Pacific perspective.

Edinur H, Mat-Ghani S, Chambers G Front Genet. 2022; 13:970549.

PMID: 36147511 PMC: 9485872. DOI: 10.3389/fgene.2022.970549.

References

Ingelman-Sundberg M . Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25(4):193-200. DOI: 10.1016/j.tips.2004.02.007. View

Ota T, Hayashida M, Ishii M, Iwao-Koizumi K, Murata S, Kinoshita K . Long PCR-based genotyping for a deleted CYP2D6 gene without DNA extraction. Drug Metab Pharmacokinet. 2014; 29(3):283-5. DOI: 10.2133/dmpk.dmpk-13-nt-116. View

Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T . Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999; 125(4):803-8. DOI: 10.1093/oxfordjournals.jbchem.a022352. View

Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K . Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res. 2008; 31(8):1549-57. DOI: 10.1291/hypres.31.1549. View

Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K . Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004; 78(8):1182-7. DOI: 10.1097/01.tp.0000137789.58694.b4. View

Ma Q, Lu A . Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2):437-59. DOI: 10.1124/pr.110.003533. View

Hayashida M, Ota T, Ishii M, Iwao-Koizumi K, Murata S, Kinoshita K . Direct detection of single nucleotide polymorphism (SNP) by the TaqMan PCR assay using dried saliva on water-soluble paper and hair-roots, without DNA extraction. Anal Sci. 2014; 30(3):427-9. DOI: 10.2116/analsci.30.427. View

Katsakiori P, Papapetrou E, Goumenos D, Nikiforidis G, Flordellis C . Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients. Indian J Pharmacol. 2011; 43(4):385-8. PMC: 3153698. DOI: 10.4103/0253-7613.83106. View

Li L, Li C, Zheng L, Zhang Y, Jiang H, Si-Tu B . Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol. 2011; 67(8):787-95. DOI: 10.1007/s00228-011-1010-y. View

10.

Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A . Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol. 2007; 21(4):419-26. DOI: 10.1111/j.1472-8206.2007.00510.x. View

11.

Zhou S, Yang L, Zhou Z, Liu Y, Chan E . Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009; 11(3):481-94. PMC: 2758120. DOI: 10.1208/s12248-009-9127-y. View

12.

Zanger U, Raimundo S, Eichelbaum M . Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2003; 369(1):23-37. DOI: 10.1007/s00210-003-0832-2. View

13.

Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K . Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000; 50(1):31-4. PMC: 2014971. DOI: 10.1046/j.1365-2125.2000.00209.x. View

14.

Soyama A, Saito Y, Kubo T, Miyajima A, Ohno Y, Komamura K . Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population. Drug Metab Pharmacokinet. 2006; 21(3):208-16. DOI: 10.2133/dmpk.21.208. View

15.

Kiyotani K, Mushiroda T, Imamura C, Tanigawara Y, Hosono N, Kubo M . Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat. 2011; 131(1):137-45. DOI: 10.1007/s10549-011-1777-7. View

16.

Myrand S, Sekiguchi K, Man M, Lin X, Tzeng R, Teng C . Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008; 84(3):347-61. DOI: 10.1038/sj.clpt.6100482. View

17.

Evans W, Relling M . Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286(5439):487-91. DOI: 10.1126/science.286.5439.487. View

18.

Miao J, Jin Y, Marunde R, Gorski C, Kim S, Quinney S . Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 2009; 9(5):319-26. PMC: 2749890. DOI: 10.1038/tpj.2009.21. View

19.

Sistonen J, Fuselli S, Palo J, Chauhan N, Padh H, Sajantila A . Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics. 2009; 19(2):170-9. DOI: 10.1097/FPC.0b013e32831ebb30. View

20.

Wolf C, Smith G, Smith R . Science, medicine, and the future: Pharmacogenetics. BMJ. 2001; 320(7240):987-90. PMC: 1117913. DOI: 10.1136/bmj.320.7240.987. View